SCHEMBL1542483

SCHEMBL1542483

COc1c(C(=O)c2cccc(C#N)c2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.44
VNN1 O95497 3/20 0.37
NR1H4 Q96RI1 1/20 0.34
CLK1 P49759 1/20 0.33
DYRK1A Q13627 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
P4HB P07237 1/20 0.33
TYMS P04818 1/20 0.33
IKBKB O14920 1/20 0.33
CHUK O15111 1/20 0.33
GSK3B P49841 2/20 0.33
MAPK14 Q16539 1/20 0.32
CYP2C8 P10632 1/20 0.32
ROCK2 O75116 1/20 0.32
ROCK1 Q13464 1/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543192 0.86 CYP3A4 (0.47) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1542980 0.86 CYP3A4 (0.49) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1542920 0.85 CYP3A4 (0.46) CYP3A4DYRK1ATUBB4ATUBBTUBA3C
SCHEMBL1542633 0.85 CYP3A4 (0.46) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1542836 0.85 CYP3A4 (0.46) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1542781 0.83 CYP3A4 (0.48) CYP3A4NR1H4CYP2C8TUBB4ATUBB
SCHEMBL1543057 0.82 CYP3A4 (0.48) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1543014 0.81 CYP3A4 (0.47) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1543290 0.81 CYP3A4 (0.47) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1543061 0.81 CYP3A4 (0.51) CYP3A4NR1H4TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP disclosed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885VNN1 2631/4885NR1H4 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.